WO2002059607A3 - Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan - Google Patents
Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan Download PDFInfo
- Publication number
- WO2002059607A3 WO2002059607A3 PCT/GB2002/000034 GB0200034W WO02059607A3 WO 2002059607 A3 WO2002059607 A3 WO 2002059607A3 GB 0200034 W GB0200034 W GB 0200034W WO 02059607 A3 WO02059607 A3 WO 02059607A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epidermal stem
- stem cells
- melanoma
- isolation
- chondroitin sulfate
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4722—Proteoglycans, e.g. aggreccan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002216296A AU2002216296A1 (en) | 2001-01-04 | 2002-01-04 | Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25977001P | 2001-01-04 | 2001-01-04 | |
US60/259,770 | 2001-01-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002059607A2 WO2002059607A2 (en) | 2002-08-01 |
WO2002059607A3 true WO2002059607A3 (en) | 2003-10-30 |
Family
ID=22986299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/000034 WO2002059607A2 (en) | 2001-01-04 | 2002-01-04 | Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002216296A1 (en) |
WO (1) | WO2002059607A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110938587A (en) * | 2020-01-08 | 2020-03-31 | 济南磐升生物技术有限公司 | Preparation method and application of epidermal stem cell suspension |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024274A1 (en) * | 1993-04-21 | 1994-10-27 | The University Of Edinburgh | Isolation, selection and propagation of animal transgenic stem cells |
WO1997013855A1 (en) * | 1995-10-10 | 1997-04-17 | Novartis Ag | Melanoma-associated protein |
WO1999047644A1 (en) * | 1998-03-18 | 1999-09-23 | Peter Maccallum Cancer Institute | Keratinocyte stem cells |
-
2002
- 2002-01-04 AU AU2002216296A patent/AU2002216296A1/en not_active Abandoned
- 2002-01-04 WO PCT/GB2002/000034 patent/WO2002059607A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024274A1 (en) * | 1993-04-21 | 1994-10-27 | The University Of Edinburgh | Isolation, selection and propagation of animal transgenic stem cells |
WO1997013855A1 (en) * | 1995-10-10 | 1997-04-17 | Novartis Ag | Melanoma-associated protein |
WO1999047644A1 (en) * | 1998-03-18 | 1999-09-23 | Peter Maccallum Cancer Institute | Keratinocyte stem cells |
Non-Patent Citations (1)
Title |
---|
GEISER M ET AL: "Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library.", CANCER RESEARCH. UNITED STATES 15 FEB 1999, vol. 59, no. 4, 15 February 1999 (1999-02-15), pages 905 - 910, XP002240701, ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002059607A2 (en) | 2002-08-01 |
AU2002216296A1 (en) | 2002-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU9231998A (en) | Antigen presenting mesenchymal stem cells | |
WO2004029219A3 (en) | Cell-based rna interference and related methods and compositions | |
AU2003226608A1 (en) | Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells | |
WO2001039722A3 (en) | B7-h1, a novel immunoregulatory molecule | |
WO2005021728A3 (en) | Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations | |
WO2002077264A3 (en) | Arrayed transfection method and uses related thereto | |
AU2001286202A1 (en) | Method of culturing mesenchymal stem cells | |
WO2004015077A3 (en) | Compositions and methods for neural differentiation of embryonic stem cells | |
WO2000046585A3 (en) | Method for enriching or depleting tumour cells obtained from a body fluid and kit suitable for this purpose | |
WO2003024406A3 (en) | Nestin-expressing hair follicle stem cells | |
WO2003003004A3 (en) | Method for identifying compounds the specifically deplete mast cells | |
AU2002306865A1 (en) | Generation of multipotent central nervous system stem cells | |
WO1999020747A3 (en) | HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS | |
AU1741601A (en) | Mesenchymal stem cells and/or progenitor cells, their isolation and use | |
EP0821064A3 (en) | Recombinant fructosyl amino acid oxidase | |
AU2003238717A1 (en) | POLYPEPTIDES HAVING Alpha- H-Alpha-AMINO ACID AMIDE RACEMASE ACTIVITY AND NUCLEIC ACIDS ENCODING THE SAME | |
WO2000069884A3 (en) | Compositions isolated from skin cells and methods for their use | |
WO2004020597A3 (en) | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations | |
WO1996002650A3 (en) | Dna, constructs, cells and plants derived therefrom | |
WO2001049721A3 (en) | Bacterial genes and proteins that are essential for cell viability and their uses | |
WO2001072970A3 (en) | Methods to prepare and use epidermal stem cells | |
WO2001092877A3 (en) | Method of identifying and/or isolating stem cells | |
WO2002059607A3 (en) | Isolation of epidermal stem cells by using the melanoma-associated chondroitin sulfate proteoglycan | |
AU2002328803A1 (en) | Marker for identifying hematopoietic stem cells | |
WO2003004616A3 (en) | Dendritic cell isolation methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |